<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200716048117N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-10-18</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of transcranial direct current stimulation (tDCS) and omega-3 supplementation on depression and weight</public_title>
      <acronym></acronym>
      <scientific_title>Determining the effectiveness of transcranial direct current stimulation (tDCS) and omega-3 supplementation on executive functions, food craving, and depressive symptoms in patients with depression and overweight</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-12-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/50663</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Factorial, Purpose: Treatment, Randomization description: Randomization method: block, randomization unit: individual, tools and randomization sequence: determined by Excel software. Allocation concealment is done by coding, Blinding description: In this double-blind study, participants, the principal investigator, the clinical caregiver, the evaluator, and the data analyst were all blind.

Description of how to blind:
Group 1: tDCS+ medicine
Group 2: SHAM+ placebo
Group 3: SHAM+ medicine
Group 4: tDCS+ placebo


Groups are hidden from the view of the research team and study participants by coding and placebo.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: mild Depression. Condition 2: Moderate depression. Condition 3: Obesity.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1:  3 sessions of transcranial direct current stimulation  (tDCS), one session per week, 4 sessions of stimulation for 15 minutes each time, and omega-3 supplement (5 cc daily, containing 736 mg (EPA) And 460 mg (DHA)). Intervention 2: Intervention group 2: Intervention group 1:  3 sessions of transcranial direct current stimulation  (tDCS), one session per week, 4 sessions of stimulation for 15 minutes each time, And omega-3 placebo supplement (5 cc daily, soybean oil). Intervention 3: Third Intervention group: 3 sessions of Sham transcranial direct current stimulation (tDCS) of the brain, one session per week, each session consists of 4 episodes of stimulation, each lasting 15 minutes, and omega-3 supplement (5 cc daily, containing 736 mg of eicosapentaenoic acid (EPA) and 460 mg docosahexaenoic acid (DHA)).0 mg DHA). Intervention 4: Control group: 3 sessions of Sham transcranial direct current stimulation (tDCS) of the brain, one session per week, each session consists of 4 episodes of stimulation, each lasting 15 minutes, and the placebo of omega-3 (5 cc daily, soybean oil).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after deleting individual IDs.

When:
Access period starts 6 months after the results are published

To whom:
Researchers working in academic and scientific institutions

Conditions:
The analyzes used in the article are allowed on the delivered data.

Where to obtain:
Requests for data / documentation should only be sent via email to the developer. Responsible person: Dr. Seyed Ali Mostafavi E-Mail: Mostafavi_a@sina.tums.ac.ir

How to obtain:
After sending an e-mail to the given documents or files, this information may be sent to the applicant's e-mail as soon as possible.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahla Tabasi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Roozbeh Hospital, Psychiatric and Psychological Research Center, South Kargar St., Tehran., Iran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1333795914</zip>
        <telephone>+98 21 5541 3540</telephone>
        <email>mahla.tabasi93@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Ali Mostafavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Roozbeh Hospital, Psychiatric and Psychological Research Center, South Kargar St., Tehran., Iran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1333795914</zip>
        <telephone>+98 21 5541 3540</telephone>
        <email>pprct@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women with depression (Beck depression score above 14)
overweight or obesity (BMI≥25)
18 to 60 years old</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Reluctance and satisfaction to participate in the study during pregnancy or lactation
Other major psychiatric illnesses such as bipolar depression, Schizophrenia, neurological diseases such as epilepsy
History of major head trauma and neurofeedback in the last two months</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F32.0</hc_code>
      <hc_code>F32.1</hc_code>
      <hc_code>E66.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Major depressive disorder, single episode, mild</hc_keyword>
      <hc_keyword>Major depressive disorder, single episode, moderate</hc_keyword>
      <hc_keyword>Obesity due to excess calories</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1:  3 sessions of transcranial direct current stimulation  (tDCS), one session per week, 4 sessions of stimulation for 15 minutes each time, and omega-3 supplement (5 cc daily, containing 736 mg (EPA) And 460 mg (DHA)).</i_keyword>
      <i_keyword>Intervention group 2: Intervention group 1:  3 sessions of transcranial direct current stimulation  (tDCS), one session per week, 4 sessions of stimulation for 15 minutes each time, And omega-3 placebo supplement (5 cc daily, soybean oil).</i_keyword>
      <i_keyword>Third Intervention group: 3 sessions of Sham transcranial direct current stimulation (tDCS) of the brain, one session per week, each session consists of 4 episodes of stimulation, each lasting 15 minutes, and omega-3 supplement (5 cc daily, containing 736 mg of eicosapentaenoic acid (EPA) and 460 mg docosahexaenoic acid (DHA)).0 mg DHA).</i_keyword>
      <i_keyword>Control group: 3 sessions of Sham transcranial direct current stimulation (tDCS) of the brain, one session per week, each session consists of 4 episodes of stimulation, each lasting 15 minutes, and the placebo of omega-3 (5 cc daily, soybean oil).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Depression score 14 and above in Beck questionnaire. Timepoint: Measurement of depression at the beginning of the study (before the intervention), and 14 and 28 days after receiving brain stimulation and omega-3 intake. Method of measurement: Beck Depression Inventory.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Scores of executive functions of individuals in Simple Strop computer software and Wisconsin card computer test. Timepoint: Measurement of executive functions at the beginning of the study (before the intervention), and 14 and 28 days after receiving brain stimulation and omega-3 intake. Method of measurement: Simple Strop computer software and Wisconsin card computer test.</sec_outcome>
      <sec_outcome>Individual cravings score in the Summary Food Trait Questionnaire (FCQ-T). Timepoint: Measurement of food craving at the beginning of the study (before the intervention), and 14 and 28 days after receiving brain stimulation and omega-3 intake. Method of measurement: Summary Food Trait Questionnaire (FCQ-T).</sec_outcome>
      <sec_outcome>People weigh in kilograms and their fat percentage with a pneumatic fat analyzer _ Model BF 511. Timepoint: Measurement of weight and fat percentage at the beginning of the study (before the intervention), and 14 and 28 days after receiving brain stimulation and omega-3 intake. Method of measurement: People weigh in kilograms and their fat percentage with a pneumatic fat analyzer _ Model BF 511.</sec_outcome>
      <sec_outcome>Appetite score in a simple appetite questionnaire SNAQ. Timepoint: Measurement of appetite at the beginning of the study (before the intervention), and 14 and 28 days after receiving brain stimulation and omega-3 intake. Method of measurement: Simple appetite questionnaire SNAQ.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-09-24</approval_date>
        <contact_name>Vice Chancellor for Research and Technology, Tehran University of Medical Sciences</contact_name>
        <contact_address>No. 1, Qods Ave., Keshavarz Blvd., Tehran., Iran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
